Asia
Reaffirms Biocon’s Capability to Manufacture Biosimilars for Patients in U.S.
Takeda will unload a portfolio of over-the-counter and prescription pharmaceutical products to Germany-based STADA for $660 million as the company continues to pare down debt from its $62 billion acquisition of Shire.
Daiichi Sankyo is taking Seattle Genetics to court over the technology the two companies used to develop antibody-drug conjugates during a partnership that spanned seven years.
AstraZeneca is significantly expanding its footprint in China with the establishment of a global research and development center in the country, as well as the launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.
A*STAR’s Institute of Bioengineering and Nanotechnology has teamed up with the Singapore Institute of Advanced Medicine Holdings Pte Ltd to explore how to better tackle nasopharyngeal carcinoma, a type of head and neck cancer, through targeted proton therapy.
Shanghai Green Valley Pharmaceuticals announced that China’s National Medical Products Administration has approved Oligomannate as new drug for the treatment of mild to moderate Alzheimer’s disease.
They announced an exclusive license deal and research agreement to develop cord-blood derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies.
In clinical trials, Talicia demonstrated 90% efficacy in the eradication of H. pylori in studies and is the only rifabutin-based therapy on the market.
One of the things the company reported that has raised eyebrows is that the drug statistically improved cognitive function in the patients as early as week 4. This would be a very quick patient response—and for that matter, given that many Alzheimer’s studies run for years, a 36-week study is at least half the length of a typical Alzheimer’s trial.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
PRESS RELEASES